Anticancer and Differentiation Properties of the Nitric Oxide Derivative of Lopinavir in Human Glioblastoma Cells.
2018
Аутори:
Basile, Maria SofiaMazzon, Emanuela
Krajnović, Tamara
Drača, Dijana
Cavalli, Eugenio
Al-Abed, Yousef
Bramanti, Placido
Nicoletti, Ferdinando
Mijatović, Sanja
Maksimović-Ivanić, Danijela
Тип документа:
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт:
Glioblastoma (GBM) is the most frequent and deadly form of primary malignant brain tumor among adults. A promising emerging approach for GBM treatment may be offered from HIV protease inhibitors (HIV-PIs). In fact, in addition to their primary pharmacological activity in the treatment of HIV infection, they possess important anti-neoplastic effects. According to previous studies, the addition of a nitric oxide (NO) donating group to parental compounds can reduce their toxicity and enhance the anticancer action of various compounds, including HIV-PIs. In this study we compared the effects of the HIV-PI Lopinavir (Lopi) and of its NO-derivative Lopinavir-NO (Lopi-NO) on the in vitro growth of LN-229 and U-251 human GBM cell lines. Lopi-NO reduced the viability of LN-229 and U-251 cells at significantly lower concentrations than the parental drug. In particular, Lopi-NO inhibited tumor cell proliferation and induced the differentiation of U-251 cells toward an astrocyte-like phenotype without triggering significant cell death in both cell types. The anticancer effect of Lopi-NO was persistent even upon drug removal. Furthermore, Lopi-NO induced strong autophagy that did not appear to be related to its chemotherapeutic action. Overall, our results suggest that Lopi-NO could be a potential effective anticancer drug for GBM treatment.
Кључне речи:
HIV protease inhibitors; Lopinavir; Lopinavir-NO; Glioblastoma; Nitric oxideИзвор:
Molecules (Basel, Switzerland), 2018, 23, 10, 2463-Финансирање / пројекти:
- Молекуларни механизми физиолошке и фармаколошке контроле инфламације и канцера (RS-MESTD-Basic Research (BR or ON)-173013)
- Ћелијски и молекулски механизми опоравка пацова од експерименталног аутоимунског енцефаломијелитиса (RS-MESTD-Basic Research (BR or ON)-173035)
DOI: 10.3390/molecules23102463
PubMed: 30261624
WoS: 000451201400059
Scopus: 2-s2.0-85054082968
URI
internal-pdf://Basile et al. - 2018 - Anticancer and Differentiation Properties of the Nitric Oxide Derivative of Lopinavir in Human Glioblastoma Cells.pdfhttp://www.mdpi.com/1420-3049/23/10/2463
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC6222694
https://radar.ibiss.bg.ac.rs/handle/123456789/3216